PT - JOURNAL ARTICLE AU - Nathan W Manning AU - Andrew Cheung AU - Timothy J Phillips AU - Jason D Wenderoth TI - Pipeline shield with single antiplatelet therapy in aneurysmal subarachnoid haemorrhage: multicentre experience AID - 10.1136/neurintsurg-2018-014363 DP - 2019 Jul 01 TA - Journal of NeuroInterventional Surgery PG - 694--698 VI - 11 IP - 7 4099 - http://jnis.bmj.com/content/11/7/694.short 4100 - http://jnis.bmj.com/content/11/7/694.full SO - J NeuroIntervent Surg2019 Jul 01; 11 AB - Background The Pipeline Embolisation Device with Shield technology (PED-Shield) is suggested to have reduced thrombogenicity. This reduced thrombogenicity may make it possible to use safely in the acute treatment of aneurysmal subarachnoid haemorrhage (aSAH) on single antiplatelet therapy (SAPT).Objective To evaluate the safety and efficacy of the off-label use of PED-Shield with SAPT for the acute treatment of aSAH.Methods Patients who underwent acute treatment of ruptured intracranial aneurysms with the PED-Shield with SAPT were retrospectively identified from prospectively maintained databases at three Australian neurointerventional centres. Patient demographics, aneurysm characteristics, clinical and imaging outcomes were reviewed.Results Fourteen patients were identified (12 women), median age 64 (IQR 21.5) years. Aneurysm morphology was saccular in seven, fusiform in five, and blister in two. Aneurysms arose from the anterior circulation in eight patients (57.1%). Six (42.9%) patients were poor grade (World Federation of Neurological Societies grade ≥IV) SAH. Median time to treatment was 1 (IQR 0.5) day. Complete or near complete aneurysm occlusion (Raymond-Roy <3) was achieved in 12 (85.7%) patients at the end of early-acute follow-up (median day 7 after SAH). Permanent, treatment-related morbidity occurred in one (7.1%) patient and one (7.1%) treatment-related death occurred. The use of a postoperative heparin infusion (n=5) was associated with a higher rate of all complications (80.0% vs 11.1%, p=0.023) and symptomatic complications (60% vs 0.0%, p=0.028). No symptomatic ischaemic or haemorrhagic complications were observed in the patients who did not receive a post-operative heparin infusion. Nine (64.3%) patients were functionally independent on discharge from the treatment centre.Conclusion The PED-Shield may be safe to use in the acute treatment of ruptured intracranial aneurysms with SAPT. Further investigation with a formal treatment registry is needed.